News
Karin Wuertz-Kozak

Becoming an AIMBE Fellow is one of the organization's most prestigious honors, representing the most accomplished individuals across academia, industry, education, clinical practice, and government.

Researchers are improving non-invasive treatment options for degenerative disc disease, an ailment that impacts 3 million adults yearly in the U.S. Using state-of-the-art gene editing technology in mesenchymal stem cells, the researchers will add to the growing field of regenerative medicine, the process of producing cellular therapies to alleviate pain and lack of mobility.

RIT faculty members, who led research initiatives as principal investigators, were honored at a reception on March 21 to celebrate the individuals who helped the university reach record awards surpassing $92 million and place among the top private research universities in the country.

WHAM-TV talks to Karin Wuertz-Kozak, professor in the Department of Biomedical Engineering, about her research on disc degeneration.

Karin Wuertz-Kozak described her lab test equipment as a gym for cells. Stretching and compressions tests using bioreactors—her lab equipment—can make a difference in understanding how cells respond to mechanical cues and how that affects disease progression, specifically for spinal disc degeneration, common to millions of Americans.

More collagen in the human body is not always good, and Professor Karin Wuertz-Kozak is investigating how disease progresses because of the increase in this important protein.